Beyond ADCs, degrader-antibody conjugates18 targeting DLK1 may be a strategy to downregulate DLK1, which could potentially sensitize ACC tumors to chemotherapy or other ADCs. Here, DLK1 is linked to adrenal cortex carcinoma.